Top Biotech Companies in NYC, NY (195)

Investor Backing & Capital Strength: Recent financings include a strategic Series C with Dassault Syst�fsmes/Medidata (March 2025) and a Series D in April 2026 led by Boehringer Ingelheim tied to CT-155 commercialization. The restructuring with Boehringer also involved additional funding as commercialization responsibilities shifted to Click.

Product Line Growth: FDA authorizations for Rejoyn (MDD, 2024) and CT-132 (migraine prevention, 2025), plus the acquisition of AspyreRx (type 2 diabetes), expand the marketed and near-market portfolio. The launch of "Click SE" and CT-155s Breakthrough designation and positive pivotal data further broaden the offering toward potential submission.

Strategic Partnerships: Collaborations with Boehringer Ingelheim, Otsuka, and Dassault Syst�fsmes/Medidata, along with a 2026 venture with Ultrahuman, indicate strong external validation and routes to commercialization. Partner activity includes Boehringer transferring commercialization duties for CT-155 to Click.

Strong Revenue Growth: Revenue expanded rapidly, with FY2025 up 83% to about $1.27B and Q1/Q2 2026 up 36% and 22% year over year, respectively. Management also raised 2026 revenue guidance to approximately $1.595–$1.605B.

Diversified Revenue Streams: Both Diagnostics and Data & Applications are expanding, with Diagnostics up 34.7% in Q1 and 20% in Q2 2026 and Insights/data licensing up 36% in Q2 alongside about $200M in new licenses. Rising oncology test volumes (28–31% YoY) and accelerating MRD tests (~4,700 in Q4 2025 to ~9,000 in Q2 2026) reinforce multiple growth engines.

Profitability: The company achieved its first GAAP-profitable quarter in Q2 2026 (net income about $5.6M; Adjusted EBITDA ~$8.0M). Guidance points to further improvement in 2026, indicating progress toward sustained profitability.

Market Expansion: International partnerships across the UK, Germany, and Japan—culminating in a first Scottish agreement in 2026—are described as tripling the network in 2025 and adding nearly 70% ex‑U.S. growth in 2026. These moves indicate a materially broader geographic footprint for evidence generation.

Strategic Partnerships: Collaborations with organizations such as NHS Greater Glasgow and Clyde, Quest Diagnostics, Abbott, TailorMed, and Unicancer reflect deepening integration at the point of care and with research stakeholders. These relationships suggest expanding routes to market and data acquisition.

Product Line Growth: New offerings like Flatiron Telescope, AI‑powered oncology datasets, and an AI data‑quality/validation framework signal active investment in products and capabilities. Conference acceptances at ISPOR/ASCO/WCLC in 2026 further underscore ongoing commercialization and scientific engagement.

Product Line Growth: Launched and acquired products are expanding at a double‑digit pace (e.g., +18% operational in Q2 2026), led by assets such as Eliquis, Padcev, the Vyndaqel family, and Lorbrena. Excluding Comirnaty and Paxlovid, revenue grew mid‑single digits, signaling healthy momentum in the core portfolio.

Cost & Operational Efficiency: A multi‑year cost realignment targets about $5.7B in net savings by end‑2026, with a further $2.5B in productivity gains planned for 2027–2029. These actions have supported improved adjusted earnings even as headline revenue normalizes post‑COVID.

Innovation-Driven Growth: A robust late‑stage pipeline and oncology expansion following the Seagen acquisition underpin future growth, with numerous pivotal study starts in 2025–2026. Company commentary highlights oncology and obesity programs as key catalysts into the back half of the decade.

Investor Backing & Capital Strength: Formation Bio closed a $372M Series D on June 26, 2024 led by a16z with significant participation from Sanofi, bringing total funding to over $600M and at a material step-up in valuation. The capital is directed toward expanding its drug pipeline and AI platform.

Strategic Partnerships: A first‑in‑class AI collaboration with Sanofi and OpenAI (announced May 2024) has already produced Muse, an AI tool for patient recruitment. Additional partnering activity includes Sanofi’s 2025 deal for gusacitinib via a Formation subsidiary, signaling expanding commercial and technology ties.

Product Line Growth: Multiple in‑licensing moves in 2025–2026 (e.g., a CNS‑penetrant TYK2 inhibitor, a miR‑124 activator, and an anti‑CD226 program) broaden the portfolio. The first participant was dosed in a Phase 1 trial (BLKR201) on June 9, 2026, marking concrete clinical progression.

Strong Revenue Growth: Total revenue increased to $255.9M in 2025 with software up and drug‑discovery more than doubling, while operating expenses declined year over year. Early 2026 also showed momentum, with first‑half revenue modestly higher and Q2 posting year‑over‑year growth.

Strategic Partnerships: New and expanded agreements—such as Bristol Myers Squibb deploying Bunsen and a July 2026 discovery collaboration with Simcere—broaden platform use and collaboration optionality. The Lilly/Ajax transaction also validated the model and supported a higher 2026 drug‑discovery outlook.

Product Line Growth: The introduction of Bunsen, an agentic AI co‑scientist, expands the software portfolio and is being deployed at scale within BMS. This product push complements growth in ACV and broader platform adoption.

Market Expansion: Public materials indicate the platform footprint has grown to 6,000+ research sites and 25+ sponsors, up from 5,500+ sites cited in late 2025, suggesting continued expansion into 2026. Geographic reach and site participation are portrayed as broadening across dozens of countries.

Strategic Partnerships: Collaborations with large biopharma (e.g., Sanofi, including a 2026 portfolio-level discussion) and integrations with ecosystem vendors like CRIO, RealTime-Devana, and eClinPro signal commercial traction and deeper ecosystem ties. These relationships are positioned to increase marketplace activity and data depth for sponsors and sites.

Innovation-Driven Growth: AI-powered pre-screening and workflow tooling launched in 2025 with ongoing case studies and integrations in 2026, aimed at accelerating enrollment and reducing site burden. The continued rollout of AI features and workflow enhancements suggests rising product maturity and adoption.

Strong Market Position & Advantage: Merck holds a clear leadership position, anchored by Keytruda—the world’s top‑selling cancer medicine at $31.7B in 2025—and strong standings in vaccines and overall scale among global pharmas. Animal health also ranks among top players, reinforcing breadth across key healthcare markets.

Innovation-Driven Growth: A broad late‑stage pipeline and scientific presence (100+ ASCO 2026 abstracts across 25+ tumor types) span oncology, vaccines, infectious disease, and cardiometabolic areas. Ongoing label expansions and new formats like subcutaneous Keytruda (including U.S. Keytruda Qlex) are adding growth vectors.

Diversified Revenue Streams: Sales draw from oncology, vaccines (e.g., Gardasil over $10.7B in 2025), hospital acute care, and a growing animal health segment. Newer launches and alliances (e.g., Winrevair, IDVYNSO, and partnered oncology assets) are contributing to mix.

Resilient & Sustainable Growth: Recent Form 990 filings indicate total revenue increased from FY2022 through FY2024 to a new high, with annual allograft distribution volumes remaining substantial. As a nonprofit reinvesting in research and operating across multiple clinical segments, growth appears steady and durable.

Strategic Partnerships: Long-term and expanded agreements with Orthofix, Centurion Therapeutics, and Kolosis BIO broaden distribution and add new allograft offerings, while OEM processing relationships (e.g., DBX) deepen channel access. These partnerships support consistent demand and market reach across orthopedics, wound care, and cardiac surgery.

Strong Market Position & Advantage: The organization is frequently described as the world’s largest tissue bank with one of the broadest allograft portfolios, extensive accreditation, and millions of grafts delivered. Consistent inclusion as a major player across relevant market reports reinforces recognized scale and presence despite sizable competitors.

Strong Market Position & Advantage: The company is positioned as a top-tier global CRO with significant scale and a broad geographic footprint, supported by a major acquisition that strengthened its competitive standing. Operational activity indicators and industry recognition are presented as reinforcing its ability to win and execute large, complex trials.

Profitability: Earnings and operating profit metrics are described as improving in 2024, with increases in GAAP net income, adjusted earnings per share, and adjusted EBITDA. These results suggest the business maintained solid margin performance even as quarterly revenue fluctuated.

Resilient & Sustainable Growth: A large backlog and a book-to-bill above 1.0 in 2024 are cited as providing multi-year revenue visibility and demand coverage. Continued backlog levels into 2025 are described as a stabilizing factor despite a softer near-term revenue trajectory.

Strong Market Position & Advantage: Company materials and third‑party recognition portray a fully integrated CRO/CCO with leadership status, including widespread involvement in recent FDA/EMA novel therapies and recognition as a leading pharmacovigilance provider.

Strategic Partnerships: Recent collaborations with Microsoft and KX are positioned to enable AI‑driven efficiencies across clinical and commercial operations, with reported improvements in cycle times supporting operational scalability.

Investor Backing & Capital Strength: The 2025 take‑private by investment groups (including Elliott and Veritas) provides financial sponsorship to pursue tech‑enabled growth and operational repositioning.

Resilient & Sustainable Growth: Revenue expanded in consecutive years, with double‑digit growth in 2023 followed by continued albeit slower growth in 2024. Trade coverage frames 2024 as a cooling market overall, suggesting the company’s trajectory reflects resilience amid a softer cycle.

Strong Market Position & Advantage: Industry rankings place the firm consistently in the MM+M Agency 100 top 20 in 2024–2025. External awards and frequent policy visibility reinforce stature in core North American healthcare‑agency and U.S. policy/access segments.

Future-Ready Strategy: Leadership additions, a unifying rebrand, and integration of advisory, medical, access, and marketing indicate a connected commercialization model. New offerings, AI/data‑driven tools, partnerships, and the “Every Patient Possible” mission signal preparation for evolving client needs.